Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML
Latest Information Update: 14 May 2024
Price :
$35 *
At a glance
- Drugs Venetoclax (Primary) ; Voruciclib (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Sponsors MEI Pharma
- 09 May 2024 According to a MEI Pharma media release, the Company has completed patient enrollment of the dose expansion cohort and enrolling dose escalation cohorts.
- 11 Apr 2024 According to a MEI Pharma media release, company plans to amend the ongoing Phase 1 study to add a Phase 2 study arm, with enrollment in the Phase 2 arm anticipated to begin in 2025. This is anticipated to generate Phase 2 data by the end of 2025.
- 26 Mar 2024 Results presented in a MEI Pharma Media Release.